Proton Pump Inhibitors to Boost the US Generics Market
Backed by patent expires on blockbuster drugs and the government support, the US generics drugs market will grow at a CAGR of 10% during 2010-2013.

Our research report has found that, Proton Pump Inhibitors (PPIs) are witnessing a shift in the number of dispensed prescriptions to generic equivalents and OTC medications. The share of generics in total sales of proton pump inhibitors reached around 50% in 2009 from 45% in 2008, which was a notable trend. Nexium, the fifth-best-selling drug in the world, will go off patent in 2014, and Aciphex does the same in 2013, foretelling even more availability for generic PPis.
The report "Booming US Generic Drug Market", effectively illustrates the potential for generic drugs sector in key therapy segments, such as Lipid regulators, Antipsychotics, Angiotensin II receptor, Human insulin, Proton pump inhibitors etc. The report also provides an important coverage on the regulatory structure with respect to generics drugs in the US. In this regard, the report illustrates some of the key acts and their important aspects.
The report is an outcome of an in-depth research and prudent analysis of the US generics drugs market that takes into account the factors affecting the market potential. The report also investigates the current market trends and effectively analyzes their impact on the market performance. Forecasting section in the report makes use of proper methods and techniques to show a realistic outlook. Overall, the report is likely to strengthen the knowledge portfolio of clients and investors.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM589.htm
Check DISCOUNTED REPORTS on: http://www.rncos.com/promotion.htm
About RNCOS:
RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals study and analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the consultants in meeting their objectives in a cost-effective and timely manner.
###
Tag Words:
generics market us
Categories: Biotech
Press Release Contact
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707